Division of Biochemistry and Molecular Biology, Siberian State Medical University, Tomsk, Russian Federation.
Cancer Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.
Curr Drug Targets. 2024;25(11):715-723. doi: 10.2174/0113894501304351240703113651.
The main epidemiological and clinical data on colorectal cancer, as well as the features of molecular pathology, are discussed in the literature review. Efforts are being putto identify promising targets, particularly small non-coding nucleotide sequences, which can lead to new treatments for this disease. The discovery of significant mutations that contribute to the development of colorectal tumors is a major step in the advancement of molecular oncology, as these mutations give rise to heterogeneous tumors that differ in their origin. These mutations play a significant role in the progression of the disease and are now being targeted for treatment. The prognosis for a disease is influenced by the patient's sensitivity to antitumor therapy. However, new approaches to finding effective targets for antitumor treatments face new fundamental challenges due to clinical issues. These issues include the epigenetic regulation of markers of oncogenesis, which allows for the development of new therapeutic strategies. RNA interference, in particular, has been linked to non-copying RNA sequences such as microRNAs. These microRNAs are associated with certain processes that can influence all aspects of oncogenesis. The diversity of microRNAs allows for a differentiated approach when treating tumors in various locations.
文献综述讨论了结直肠癌的主要流行病学和临床数据,以及分子病理学特征。目前正在努力寻找有前途的靶点,特别是小非编码核苷酸序列,这可能为这种疾病带来新的治疗方法。发现导致结直肠肿瘤发展的重要突变是分子肿瘤学进展的重要一步,因为这些突变导致起源不同的异质性肿瘤。这些突变在疾病的进展中起着重要作用,现在正在针对这些突变进行治疗。疾病的预后受患者对抗肿瘤治疗的敏感性影响。然而,由于临床问题,寻找抗肿瘤治疗有效靶点的新方法面临新的基本挑战。这些问题包括致癌标志物的表观遗传调控,这允许开发新的治疗策略。特别是 RNA 干扰与非复制 RNA 序列(如 microRNAs)有关。这些 microRNAs 与某些可以影响肿瘤发生各个方面的过程有关。microRNAs 的多样性允许在治疗不同部位的肿瘤时采用差异化方法。